PXR*1B基因多态性与氨氯地平稳态谷浓度和降压疗效的相关性研究

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (10): 1143-1147.

PXR^*1B基因多态性与氨氯地平稳态谷浓度和降压疗效的相关性研究

张桂香^1,2, 袁洪¹, 阳国平¹, 黄志军¹

¹中南大学湘雅三医院临床药理中心, ²湖南省第二人民医院药剂科,长沙 410006,湖南

收稿日期:2010-08-11 修回日期:2010-10-16 发布日期:2020-09-16
通讯作者: 黄志军,男,硕士,研究方向:心血管临床药理学。Tel: 0731-88618339 E-mail: mhzj@163.com
作者简介:张桂香,女,硕士研究生,研究方向:临床药理学和临床药学。Tel: 13574887542 E-mail: duoduo0217@163.com
基金资助:
国家“重大新药创制”科技重大专项(2009ZX09501-032);863计划(2009AA022703);湖南省卫生厅重点项目(A2007-004)

Correlation study of PXR^*1B polymorphisms and steady-state trough concentration and its antihypertensive effect of amlodipine

ZHANG Gui-xiang^1,2, YUAN Hong², YANG Guo-ping², HUANG Zhi-jun²

¹Center of Clinical Pharmacology, The 3rd Xiangya Hospital of Central South University, ²Department of Pharmacy, Second People's Hospital of Hunan Province, Changsha 410006, Hunan, China

Received:2010-08-11 Revised:2010-10-16 Published:2020-09-16

摘要/Abstract

摘要： 目的: 探讨PXR11193T＞C、8055 C＞T及PXR^*1B(由11193T＞C和8055 C＞T构成)对轻中度原发性高血压患者服用氨氯地平的稳态谷浓度及其降压疗效的影响。方法: 采用基因测序的方法测定PXR11193T＞C、8055C＞T基因型。采用PHASE V.2.1对PXR^*1B单倍体进行分析。62例轻中度原发性高血压患者进入氨氯地平临床试验。患者每天早上服用5 mg氨氯地平,疗程为8周。测定治疗前、治疗4周和8周后的血压。采集第8周服药前血样,用HPLC-MS/MS方法检测氨氯地平的血药浓度。使用SPSS 13.0软件包比较不同基因型组间氨氯地平的稳态谷浓度及降压疗效的差异。结果: 61例轻中度原发性高血压患者完成了药物试验。氨氯地平的有效率为63.9％。PXR11193T＞C、8055 C＞T位点及PXR^*1B不同基因型组间氨氯地平稳态谷浓度和降压疗效差异无统计学意义(P＞0.05)。结论: PXR1193T＞C、8055C＞T及PXR^*1B对原发性高血压患者连续服用氨氯地平的稳态谷浓度及降压疗效无显著影响。

关键词: 孕烷X受体, 基因多态性, 氨氯地平, 浓度, 降压疗效

Abstract: AIM: To investigate the effect of PXR11193T＞C,8055 C＞T and PXR^*1B (contain 11193T＞C and 8055C＞T) on the steady-state trough concentration and antihypertensive effect of amlodipine in essential hypertension patients. METHODS: Genotyping of PXR11193T＞C and 8055 C＞T were determined by pyrosequencing sequenator. PXR^*1B was analyzed by PHASE V.2.1. 62 essentialhypertension patients rolled the clinical trial. They were treated with amlodipine for 8 weeks, according to once a day, 5 mg per time in every morning. Blood pressure was measured at 0, 4, 8-week. At 8-week the venous blood samples were collected before amlodipine administration. Plasma was used to determined concentration of amlodipine by HPLC-MS/MS. Statistical analyses were performed by the SPSS 13.0 software for Windows. RESULTS: 61 of patients finished the clinical trial and the effective power of amlodipine was 63.9％. There was no significantly difference of the steady-state trough concentration and antihypertensive effect of amlodipine among genotypes of PXR11193T＞C,8055 C＞T and PXR^*1B(P＞0.05). CONCLUSION: PXR polymorphisms does not significantly affect the steady-state trough concentration and antihypertensive effect of amlodipine in essential hypertension patients.

Key words: Pregnane X receptor, Gene polymorphism, Amlodipine, Concentration, Antihypertensive

中图分类号:

R969

张桂香, 袁洪, 阳国平, 黄志军. PXR^*1B基因多态性与氨氯地平稳态谷浓度和降压疗效的相关性研究[J]. 中国临床药理学与治疗学, 2010, 15(10): 1143-1147.

ZHANG Gui-xiang, YUAN Hong, YANG Guo-ping, HUANG Zhi-jun. Correlation study of PXR^*1B polymorphisms and steady-state trough concentration and its antihypertensive effect of amlodipine[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(10): 1143-1147.

参考文献

[1] 陈卿, 吴健, 伍建红, 等.高血压患者长期服用氨氯地平对动脉弹性和左心室肥大的影响[J]. 中国动脉硬化杂志, 2007, 15(7): 503-505.
[2] Park JY, Kim KA, Lee GS, et al. Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects[J]. Clin Ther, 2004, 26(5): 715-723.
[3] Kim KA, Park PW, Lee OJ, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects[J]. Clin Pharmacol Ther, 2006, 80(6): 646-656.
[4] Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet, 2001, 27(4): 383-391.
[5] Kim KA, Park PW, Park JY. Effect of ABCB1(MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects[J]. Br J Clin Pharmacol, 2007, 63(1): 53-58.
[6] Fukuen S, Fukuda T, Matsuda H, et al.Identification of the novel splicing variants for the hPXR in human livers[J]. Biochem Biophys Res Commun, 2002, 298(3): 433-438.
[7] Uno Y, Sakamoto Y, Yoshida K, et al. Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter[J]. J Hum Genet,2003, 48(11): 594-597.
[8] 刘国仗, 胡大一, 陶萍, 等.心血管药物临床试验评价方法的建议[J].中华心血管病杂志, 1998, 26(1): 5-1l.
[9] Oleson L, von Moltke LL, Greenblatt DJ, et al. Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor(PXR) gene associated with variability in cytochrome P450 3A(CYP3A) metabolism[J]. Xenobiotica, 2010, 40(2): 146-162.
[10] Miura M, Satoh S, Inoue K, et al. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients[J]. Steroids, 2008, 73(11): 1052-1059.
[11] Qiu H, Mathäs M, Nestler S, et al. The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability[J]. Pharmacogenet Genomics, 2010, 20(3): 167-178.

[1]	汪飞, 杭永付, 王未. 重症患者肾功能亢进对替考拉宁血药浓度影响分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1043-1048.
[2]	余巧玲, 翟葳葳, 刘平, 邱博, 吴惠珍. 利伐沙班血药浓度监测的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 809-817.
[3]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[4]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[5]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[6]	柳彤, 徐佳明, 王金伙, 尹磊, 陈永权, 郭建荣. 急性等容血液稀释自体血体外隔离期间血浆中麻醉药物浓度变化及回输后对麻醉效应的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 413-418.
[7]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[8]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[9]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[10]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[11]	杜文鹏, 敖检根, 陶祎, 吴观胜, 何佳珂. 自身免疫疾病患者他克莫司稳态血药浓度影响因素的研究[J]. 中国临床药理学与治疗学, 2022, 27(6): 645-651.
[12]	武元竹, 刘俊, 杨魁, 彭静, 栾家杰, 韦俊, 张大发, 宋帅, 袁小龙, 王中方, 张年宝, 解丹, 姜鹏, 范洁. 安徽地区汉族人群CYP2C9*3和VKORC1-1639G>A基因多态性分布及对华法林稳定剂量的影响[J]. 中国临床药理学与治疗学, 2022, 27(6): 652-659.
[13]	陈佳音, 王丽, 王立军, 童刚领, 马洁, 陈西敬, 卢杨. 有机阳离子转运体基因多态性与奥沙利铂毒性及疗效的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(2): 171-177.
[14]	何杰, 刘冬雪, 钟羚君, 邵华, 胡琳璘. 重症患者体内米卡芬净暴露量有限采样法估算模型的建立[J]. 中国临床药理学与治疗学, 2022, 27(11): 1264-1271.
[15]	高茸, 马亚中, 赵海霞, 王肇源, 张伟红, 袁海龙. 苯磺酸氨氯地平片在中国健康受试者中的生物等效性研究[J]. 中国临床药理学与治疗学, 2022, 27(1): 56-62.